S6.14.2 – Goals of the Stephen A. Harrison Patient Advocacy Fellowship Program
In this conversation, the organizers of the Stephen A. Harrison Patient Advocacy Fellowship Program discuss their goals for the program.
October 9, 2025
In this conversation, the organizers of the Stephen A. Harrison Patient Advocacy Fellowship Program discuss their goals for the program.
Roger Green drives this conversation, which focuses on two issues: impact of US government chaos on the MASH community and how competition might evolve in the in-office scanning market.
In this conversation from April, Naim Alkhouri joins Roger Green to reminisce about his long relationship with Stephen Harrison and announce his (then) new role as Chief Academic Officer at Summit Clinical Research.
Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to wrap up the Steatotic Think-Thank on SLD, Mike Betel shares lessons from his 30-day Glucose Challenge, and Naim Alkhouri remembers Stephen Harrison while sharing his vision for the future of clinical trials and medical education.
Hepatologist and Hepatology Key Opinion Leader Sven Francque joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss other agents in development with unique modes of action and the ways that metabolic vs. pleiotropic effects will drive future drug choices.
This diverse episode includes a discussion of effective behavioral therapies, a look at drug development we did not discuss in prior episodes, and a sober discussion on how to do our best in addressing the important Washington Challenges under Trump and RFK Jr.
Hepatologist and Hepatology Key Opinion Leader Sven Francque joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss the current and future roles of NITs in Drug Development.
This episode includes a discussion on patient management and self-management from the Global Think-Thank on Steatotic Liver Disease plus a segment from April’s Drug Development roundtable focusing on NITs in clinical trials. This week’s Newsmaker is Jose Willemse, President of the Dutch Liver Patients Association.
On the first anniversary of Stephen Harrison’s passing, we take an episode to remember our co-founder and colleague, Stephen Harrison, his contributions to MASH and how his legacy moves forward.
The opening portion of SurfingMASH’s April roundtable on drug development looks at developments in the FGF-21 mode of action and, more generally, treatment of patients with cirrhosis, with tremendous enthusiasm.